Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
0,925€
1,37%
Echtzeit-Aktienkurs Mesoblast Ltd.
Bid:
Ask:
Nachrichten zur Mesoblast Ltd. Aktie
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for…
Dr. Gregory George MD PhD Joins Mesoblast Board
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…
Personalized Cell Therapy Market: Growing at a CAGR of 25% From 2024-2032 | Pfizer, CARsgen Therapeutics, Mesoblast Ltd
Bristol Myers Squibbs FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, tackling unmet cancer needs.…
Mesoblast reports Q2 results
…
Mesoblast prepares to launch FDA-approved therapy for Pediatric Steroid-Refractory aGVHD
…
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
Mesoblast stock climbs 80% in a month following the FDAs approval of Ryoncil as the only approved therapy for SR-aGVHD…
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
…
Mesoblast stock soars on FDA approval of Ryoncil By Investing.com
Mesoblast stock soars on FDA approval of Ryoncil…
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
The FDA approves Mesoblasts Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.…
US FDA approves Mesoblasts cell therapy for graft-versus-host disease By Reuters
US FDA approves Mesoblasts cell therapy for graft-versus-host disease…
Mesoblast to join Nasdaq Biotechnology Index
…
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify key target population for Mesoblast allogeneic cell therapy…
Mesoblast Aktie: Wachstumsdruck verwandelt in Chancen
Die australische Biotechnologie-Firma Mesoblast verzeichnete im vergangenen Monat eine beachtliche Entwicklung an der Börse. Der Aktienkurs des Unternehmens, das sich…
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…
Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc.
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Degenerative Disc Disease - Pipeline Insight, 2024" clinical trials has…
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to…
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines…